Statement: the primary trial and the secondary trial do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18.
Primary_evidence: Inclusion Criteria:   Previous participation in study 971-ONC-0028-080. Exclusion Criteria:   Subjects who had not previously participated in study 971-ONC-0028-080.
Secondary_evidence: DISEASE CHARACTERISTICS:   Diagnosis of breast cancer at high risk for recurrence, defined by one of the following:   Stage IV that is free of all known disease after eradication by surgery, radiotherapy, or chemotherapy   May or may not have elevated CA 15-3 or CEA levels   Stage I, II, or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease, but have rising CA 15-3 or CEA levels   Rising CA 15-3 and CEA defined as a prior normal level increased on 2 consecutive occasions at least 2 weeks apart   For patients with a significant history of smoking who have a chronically elevated CEA (less than 15), CEA must be increased at least 1.5 times the uppermost chronic value on 2 consecutive occasions at least 2 weeks apart   Stage III and completed adjuvant therapy no more than 24 months ago   Recurrence in the ipsilateral axilla after lumpectomy and/or axillary dissection or modified radical mastectomy   Recurrence in the ipsilateral breast after lumpectomy and/or axillary dissection   Stage II with at least 4 positive axillary nodes and completed adjuvant therapy no more than 24 months ago   Stage IV that is stable on hormonal therapy   Hormone receptor status:   Not specified   PATIENT CHARACTERISTICS:   Age:   18 and over   Sex:   Male or female   Menopausal status:   Not specified Performance status:   Karnofsky 80-100%   Life expectancy:   Not specified   Hematopoietic:   Lymphocyte count at least 500/mm^3   WBC at least 3,000/mm^3   Hepatic:   AST no greater than 1.5 times upper limit of normal (ULN)   Alkaline phosphatase no greater than 1.5 times ULN   Renal:   Creatinine no greater than 1.5 times ULN   Cardiovascular:   No clinically significant New York Heart Association class III or IV cardiac disease   Other:   Not pregnant   Negative pregnancy test   Fertile patients must use effective contraception   No prior seafood allergy   No known prior immunodeficiency or autoimmune disease   No other active cancer except basal cell or squamous cell skin cancer   PRIOR CONCURRENT THERAPY:   Biologic therapy:   At least 6 weeks since prior immunotherapy   No prior vaccine with any of the antigens in this study   Chemotherapy:   See Disease Characteristics   At least 4 weeks since prior chemotherapy   No concurrent chemotherapy   Endocrine therapy:   See Disease Characteristics   Radiotherapy:   See Disease Characteristics   At least 4 weeks since prior radiotherapy   No concurrent radiotherapy   Surgery:   See Disease Characteristics   At least 4 weeks since prior surgery   Concurrent surgery for local recurrence allowed if patient remains disease free